Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen.

Autor: Nannini LJ; Pulmonary Section, Hospital E Perón, Universidad Nacional Rosario, Granadero Baigorria, Argentina.; Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Granadero Baigorria, Argentina., Neumayer NS; Pulmonary Section, Hospital E Perón, Universidad Nacional Rosario, Granadero Baigorria, Argentina., Brandan N; Pulmonary Section, Hospital E Perón, Universidad Nacional Rosario, Granadero Baigorria, Argentina., Fernández OM; Pulmonary Section, Hospital E Perón, Universidad Nacional Rosario, Granadero Baigorria, Argentina., Flores DM; Pulmonary Section, Hospital E Perón, Universidad Nacional Rosario, Granadero Baigorria, Argentina.
Jazyk: angličtina
Zdroj: European clinical respiratory journal [Eur Clin Respir J] 2022 Aug 08; Vol. 9 (1), pp. 2110706. Date of Electronic Publication: 2022 Aug 08 (Print Publication: 2022).
DOI: 10.1080/20018525.2022.2110706
Abstrakt: Overreliance on short-acting β 2 -agonists (SABA) has been a common feature of asthma management globally for at least 30 years. However, given the evidence against the long-term use of SABA, including potentially increased risk of exacerbations, emergency room visits, overall healthcare resource utilization, and mortality, the latest Global Initiative for Asthma report no longer recommends SABA only therapy. Since 2014, we implemented an ICS-containing reliever strategy at our asthma center at the G Baigorria Hospital in Argentina; we only administered budesonide/formoterol via a single inhaler device across the spectrum of asthma severity and completely eliminated the use of SABA therapy. In this article, we compare hospitalization data from our center, previously reported in the EAGLE study (when inhaled corticosteroids plus as-needed SABA was administered) for the years 1999 and 2004 with data from 2017 to 2018 (when budesonide/formoterol in a single inhaler device was administered as maintenance and/or anti-inflammatory reliever therapy [MART/AIR] without any SABA) from our center, to assess the impact of two distinct asthma management strategies on asthma-related hospitalizations. MART/AIR regimens in our SABA-free center reduced asthma hospitalizations from 9 (1999 and 2004) to 1 (2017 and 2018) (Fisher's exact test, p = 0.031; odds ratio = 0.11; 95% confidence interval [CI] = 0.013-0.98); the hospitalization rate was reduced by 92% (1.47% in 1999 and 2004 to 0.12% in 2017 and 2018). Our data provide preliminary real-world evidence that MART/AIR with budesonide/formoterol simultaneously with SABA elimination across asthma severities is an effective asthma management strategy for reducing asthma-related hospitalizations.
Competing Interests: LJN has received personal fees as a speaker for Novartis and AstraZeneca, fees for participating in an advisory board from Sanofi Genzyme and AstraZeneca, and personal fees to travel to meetings from Boehringer Ingelheim and AstraZeneca. OMF has received personal fees as a speaker for AstraZeneca and fees to travel to meetings from Teva Pharmaceuticals and AstraZeneca. NSN, NB, and DMF do not have any conflicts of interest.
(© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.)
Databáze: MEDLINE
Externí odkaz: